FDA Issues Revised Guidance on Biosimilar Development and BPCIA | Goodwin

On September 20, 2021, the FDA issued a revised final guidance for industry entitled “Questions and Answers on Biosimilar Development and the BPCI Act” and a third revision to its draft...

Related Keywords

,Biosimilar Development ,Draftq As On Biosimilar Development ,